Safety study of GSK4425689A in healthy adults
Part of Infections clinical trials.
This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 and weigh between 110–220 pounds with a healthy BMI
- Be in generally good health with no serious ongoing medical conditions
- Have normal liver, kidney, and blood test results
- Cannot be pregnant, planning pregnancy, or breastfeeding
- No history of malaria vaccine trials, severe allergies, or heart rhythm problems
- Stop all other medications, supplements, and recreational drugs 2+ weeks before the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.
This trial tests how a new drug (GSK3772701) interacts with another common drug (midazolam) in healthy volunteers. It aims to see if one affects how the other works in the body and will help determine safe dosing for future studies.
This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.
This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.